Novel approaches to support therapeutic development in ultra-rare cancers
The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Specific areas of interest include, but are not limited to, the following examples: • Development of
| Agency | Food and Drug Administration |
|---|---|
| Status | Forecasted |
| Opportunity number | FOR-FD-26-004 |
| Posted date | 08/04/2025 |
| Expected number of awards | 2 |
| Assistance Listing (CFDA) | 93.103 |
| Description | The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Specific areas of interest include, but are not limited to, the following examples: • Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers. • Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers. • Development and implementation of a collaborative multi-stakeholder effort to |
| Agency contact | patrick.johnson@fda.hhs.gov |
| Official listing | https://www.grants.gov/search-results-detail/360223 |